Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 50,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $80.94, for a total transaction of $4,047,000.00. Following the sale, the director directly owned 780,073 shares of the company’s stock, valued at approximately $63,139,108.62. This trade represents a 6.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Liquidia Stock Down 2.2%

NASDAQ:LQDA traded down $1.76 during mid-day trading on Wednesday, hitting $79.47. The company had a trading volume of 1,738,308 shares, compared to its average volume of 1,851,688. The business has a fifty day simple moving average of $62.48 and a 200-day simple moving average of $46.03. The firm has a market capitalization of $7.07 billion, a price-to-earnings ratio of 567.68 and a beta of 0.55. Liquidia Corporation has a 1 year low of $12.88 and a 1 year high of $82.96. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue was up 4187.1% compared to the same quarter last year. Equities analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LQDA. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. HC Wainwright upped their price objective on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $68.88.

Institutional Trading of Liquidia

A number of hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia in the fourth quarter valued at $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the 2nd quarter worth $25,000. FNY Investment Advisers LLC acquired a new position in Liquidia during the 3rd quarter worth $34,000. Covestor Ltd increased its position in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after purchasing an additional 4,927 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).